Plain language summary: Can declines in prostate-specific antigen level indicate how long patients with advanced prostate cancer will live when treated with enzalutamide?

Hussain, Maha; Sternberg, Cora N; Efstathiou, Eleni; Fizazi, Karim; Shen, Qi; Lin, Xun; Sugg, Jennifer; Steinberg, Joyce; Noerby, Bettina; Giorgi, Ugo De; Shore, Neal D; Saad, Fred

Hussain, Maha; Sternberg, Cora N; Efstathiou, Eleni; Fizazi, Karim; Shen, Qi; Lin, Xun; Sugg, Jennifer; Steinberg, Joyce; Noerby, Bettina; Giorgi, Ugo De; Shore, Neal D; Saad, Fred.

Affiliation

Hussain M; Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Sternberg CN; Englander Institute for Precision Medicine, Meyer Cancer Centre, Weill Cornell Medicine, New York, New York.
Efstathiou E; MD Anderson Cancer Center, Houston, Texas.
Fizazi K; Institut Gustave Roussy, University of Paris Saclay, Villejuif, France.
Shen Q; Pfizer Inc., Collegeville, Pennsylvania.
Lin X; Pfizer Inc., La Jolla, California.
Sugg J; Astellas Pharma Inc., Northbrook, Illinois.
Steinberg J; Astellas Pharma Inc., Northbrook, Illinois.
Noerby B; Sygehus, Lillebaelt, Vejle, Denmark.
Giorgi U; IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, Italy.
Shore ND; Carolina Urologic Research Center, Myrtle Beach, South Carolina.
Saad F; University of Montreal Hospital Center, Montreal, Canada.

Future Oncol ; 19(29): 1953-1960, 2023 Sep.

Article in En | MEDLINE | ID: mdl-37585665

Key words

advanced prostate cancer; androgen deprivation therapy; enzalutamide; lay summary; nonmetastatic castration-resistant prostate cancer; overall survival; plain language summary; prostate-specific antigen

Fulltext

XML

PubMed Links

Search on Google